Trial Profile
A Phase 1, First-in-Human Study of ImmunoPET Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504, an Anti-PD-L1 Tracer for Positron Emission Tomography in Patients With Advanced PD-L1 Positive Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2022
Price :
$35
*
At a glance
- Drugs Zirconium 89 DFO REGN 3504 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors Regeneron Pharmaceuticals
- 07 Feb 2022 Status changed from recruiting to discontinued.
- 29 Nov 2021 Study design and the number of arms have been amended.
- 29 Nov 2021 Planned End Date changed from 4 Nov 2022 to 13 Nov 2023.